<h4>Researchers will analyze materials from six disease study sites across US</h4>
Multi-omics is a research approach that leverages the power of several different “omics” data types at once to build a detailed picture of factors that contribute to human health and disease.
The National Institutes of Health (NIH) is channeling $50.3 million over the next five years into a new consortium dedicated to advancing the generation and analysis of multi-omics data for human health research. As part of this team, Washington University in St. Louis is establishing and will lead a central production center that functions as a hub for multi-omics analyses for materials from consortium members at each of six disease study sites identified by the NIH.
<a href="https://chemistry.wustl.edu/people/gary-patti?&amp;_ga=2.245277708.866671225.1710415924-433581621.1709556186">Gary Patti</a>, the Michael and Tana Powell Professor of Chemistry in Arts &amp; Sciences and a professor of medicine and of genetics at the School of Medicine, and <a href="https://genome.wustl.edu/people/ting-wang/?_ga=2.245277708.866671225.1710415924-433581621.1709556186">Ting Wang</a>, head of the Department of Genetics at the School of Medicine and the Sanford C. and Karen P. Loewentheil Distinguished Professor of Medicine, are principal investigators with the new consortium. Patti, who recently founded a multi-omics company called <a href="https://panomebio.com/">Panome Bio</a>, is an innovator in multi-omics research, and Wang is involved in multiple other NIH consortia, such as the <a href="https://medicine.wustl.edu/news/nih-funds-centers-to-improve-diversify-reference-human-genome/?_ga=2.20933809.866671225.1710415924-433581621.1709556186">Human Pangenome Reference Consortium</a>.
<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Washington_University_in_St_Louis_Wash_U_leads_new_multi_omics_production_center_for_NIH_research_consortium_Patti_fa8e4a9e2a/Washington-University-in-St.-Louis-WashU-leads-new-multi-omics-production-center-for-NIH-research-consortium-Patti.jpg" alt="Washington University in St. Louis: WashU leads new multi-omics production center for NIH research consortium: Patti"/>
Collaborators will take advantage of cutting-edge resources at Washington University, such as the <a href="https://research.wustl.edu/core-facilities/center-for-metabolomics-and-isotope-tracing/?_ga=2.243156107.866671225.1710415924-433581621.1709556186">Center for Proteomics, Metabolomics, and Isotope Tracing</a> on the Danforth Campus. The university estimates the value of its portion of the new grant at $19.2 million.
“Most human diseases have complex origins that are influenced by a combination of genetic and environmental components such as diet, physical activity, exposure to pollutants and social determinants,” Patti said. “We are working to understand how disease develops in a person by studying the flow of molecular information at multiple levels of ‘omics’ in parallel.”
“*This consortium model eliminates one important barrier to progress by making it easier to collect multi-omics data from the same sets of samples and developing collaborative teams with the appropriate expertise to harmonize and integrate the results,*” he said.
<h4>A more holistic view</h4>
Multi-omics incorporates several “omics” data types, including genomics, epigenomics, transcriptomics, proteomics and metabolomics. Each of these data types reveals distinct information about different aspects of a biological system, and leveraging all these data types at once is becoming increasingly possible with advances in high-throughput technologies and data science.
The integration of multiple types of data from an individual participant’s biological sample can provide a more holistic view of the molecular factors and cellular processes involved in human health and disease, including untangling genetic and non-genetic factors in health and disease. This approach offers great promise in areas such as defining disease subtypes, identifying biomarkers and discovering drug targets.
<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Washington_University_in_St_Louis_Wash_U_leads_new_multi_omics_production_center_for_NIH_research_consortium_Wang_017d37d6a5/Washington-University-in-St.-Louis-WashU-leads-new-multi-omics-production-center-for-NIH-research-consortium-Wang.jpg" alt="Washington University in St. Louis: WashU leads new multi-omics production center for NIH research consortium: Wang"/>
“*With each additional layer of omics information comes more clues about biology,” Wang said. “I’m really excited about the work we will do in this consortium to integrate genomics, proteomics and metabolomics data. This is the future of systems biology.*”
“*Beyond gaining insights into individual diseases, the primary goal of this consortium is to develop scalable and generalizable multi-omics research strategies as well as methods to analyze these large and complex datasets,” said Joannella Morales, a National Human Genome Research Institute (NHGRI) program director involved in leading the consortium. “We expect these strategies will ultimately be adopted by other research groups, ensuring the consortium’s work will have broad and long-lasting impacts for clinical research.*”
<a href="https://www.nih.gov/news-events/news-releases/nih-awards-503-million-multi-omics-research-human-health-disease">Funding for the consortium</a> will support work at six disease study sites, which will examine conditions such as fatty liver diseases, hepatocellular carcinoma, asthma, chronic kidney disease and preeclampsia, among others.
The sites will enroll research participants, at least 75% of whom will be from ancestral backgrounds underrepresented in genomics research. The sites also will collect data on participants’ environments and social determinants of health to be used in conjunction with the multi-omics data. Combining the multi-omic and environmental data can offer an even more comprehensive view of the factors that contribute to disease risk and outcomes.
Specimens provided by participants will be processed at the omics production center at Washington University, which will use high-throughput molecular assays to generate genomics, epigenomics, transcriptomics, proteomics and metabolomics data that will be analyzed to generate molecular profiles of disease and non-disease states.
A data analysis and coordination center will then incorporate all of these data into large, organized datasets that will be made available to the scientific community for further studies.
“*This is a rare opportunity to bring together a bunch of scientists with highly complementary expertise. I expect it to inspire breakthroughs in leveraging multi-omics approaches to understand disease,*” said <a href="https://chemistry.wustl.edu/people/leah-shriver?_ga=2.10043580.866671225.1710415924-433581621.1709556186">Leah Shriver</a>, a research associate professor of chemistry in Arts &amp; Sciences and a co-investigator on the research team.
“*Multi-omics studies are at the forefront of biomedical research and promise to advance our understanding of disease onset and progression,” said Erin Ramos, deputy director of NHGRI’s Division of Genomic Medicine. “All while potentially providing important clues for treatment design and drug-discovery efforts. This new consortium is an important step in making those advances a reality.*”
The award is funded jointly by NHGRI, the National Cancer Institute and the National Institute of Environmental Health Sciences.

WashU leads new multi-omics production center for NIH research consortium

Colorectal cancer rates in adults under age 50 have been increasing in the U.S. and globally. The risk of developing such cancers has been rising with each generation since the 1950s, but scientists have not been able to explain why. Understanding the underlying causes will help design prevention strategies for future generations.
<a href="https://surgery.wustl.edu/people/yin-cao/">Yin Cao, ScD</a>, an associate professor of surgery and of medicine in the <a href="https://publichealthsciences.wustl.edu/">Public Health Sciences Division</a> at Washington University School of Medicine in St. Louis, is leading an international team seeking to understand what is driving the increase in early-onset colorectal cancers globally. Her team will do so with an award of up to $25 million over five years from <a href="https://cancergrandchallenges.org/">Cancer Grand Challenges</a>, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). According to the organization, the mission of Cancer Grand Challenges is to unite the world’s brightest minds against cancer’s toughest challenges.
The team is funded by Cancer Research UK, the National Cancer Institute, the Bowelbabe Fund for Cancer Research UK, and Institut National Du Cancer in France, through Cancer Grand Challenges.
“The alarming rise of colorectal cancer in young people around the world demands immediate action,” said Cao, also a research member of <a href="https://siteman.wustl.edu/">Siteman Cancer Center</a>, based at Barnes-Jewish Hospital and Washington University School of Medicine. “We used to think colorectal cancer was a disease of the older population, but in the past two decades, the median age of diagnosis for this cancer in the U.S. dropped from 72 to 66 years. Our team aims to unravel and ultimately reverse the intricate network of causal factors throughout the life course that contribute to early-onset colorectal cancer.”
The award will provide funding for Cao’s research team — named Pathways, Risk Factors and Molecules to Prevent Early-onset Colorectal Tumors (PROSPECT) — to develop disruptive and transdisciplinary approaches to address this challenge. Among 176 international teams that applied, Cao’s team is one of five to receive funding this year through Cancer Grand Challenges. The other funded teams are focused on cancer inequities, solid tumors in children, and T cell receptors.
Cao co-leads the team with Andrew Chan, MD, at Massachusetts General Hospital (MGH). The research team also involves nine interdisciplinary co-investigators across the globe, including <a href="https://chemistry.wustl.edu/people/gary-patti">Gary Patti, PhD</a>, the Michael and Tana Powell Professor of Chemistry at Washington University. Patti, a pioneer of mass spectrometry-based technologies, will lead state-of-the-art molecular and metabolic analyses to identify possible new risk factors.
Cao’s lab has led the field of early-onset colorectal cancer research by uncovering risk factors throughout the life course that may contribute to the cancer’s rising incidence, such as obesity; diabetes; metabolic comorbid conditions such as high blood pressure and high cholesterol; prolonged sitting; poor diet; sugar-sweetened beverages; alcohol drinking patterns; and birth via cesarean delivery. Cao’s team also leads work in early detection and understanding molecular pathways of this cancer.
Building upon this past research, Cao will lead the first consortium dedicated to early-onset colorectal cancer risk factor discovery. The PROSPECT Global Consortium will have support from more than 15 international cohorts and electronic health record-based biobanks from high-, middle- and low-income countries. Her team will examine known risk factors and seek to find new ones. The query will encompass environmental exposures throughout the life course, including lifestyle, genetic, environmental and social factors. The team then will characterize possible causal factors and the cumulative impact of exposures over the life course on colorectal cancer initiation and progression, using animal models.
Cao also will also collaborate with clinicians at Siteman Cancer Center’s <a href="https://siteman.wustl.edu/treatment/cancer-types/colorectal/young-onset-colorectal-cancer-program/">Young Onset Colorectal Cancer Program</a> to collect biospecimens along the continuum of early-onset colorectal cancer development. The researchers will analyze these specimens to characterize the cumulative effects of risk factors for early-onset colorectal cancer on the biochemical and molecular states of tissues.
“An understanding of what causes early-onset cancers is important for the development of interventions based on an individual’s risk so that we can prevent disease and death,” Cao said. “Our goal is to maximally integrate human and mechanistic evidence to develop precision prevention strategies.”
In addition to identifying risk factors and evaluating causal factors, the team also will translate these findings to develop and test prevention strategies, including precision prevention trials and community risk-assessment trials.
“By pushing the boundaries of our individual fields, we hope to move quickly to identify opportunities for preventive interventions that can benefit younger populations,” Cao said. “It’s a joint adventure shared by scientists, providers, patients and the public under a unified goal: shaping a hopeful and healthier future for our younger generations.”

Preventing early-onset colorectal cancers aim of $25 million award

For over a century, cancer cell metabolism has been viewed as something of a paradox. New work from researchers at Washington University in St. Louis shows that it might not be such an anomaly after all. The study is published Aug. 15 in <a href="https://www.cell.com/molecular-cell/fulltext/S1097-2765(22)00703-1">Molecular Cell</a>.
<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Washington_University_in_St_Louis_Shutterstock_Sugar_metabolism_is_surprisingly_conventional_in_cancer_Mitochondria_the_cell_s_powerhouses_play_an_active_role_in_most_cancers_726527b95c.jpg" alt="Washington University in St. Louis /Shutterstock: Washington University in St. Louis/Shutterstock: Mitochondria — the cell’s powerhouses — play an active role in most cancers. Research from Washington University in St. Louis shows that cancer cells only waste glucose (sugar) because transport into mitochondria is too slow. The study has implications for targeting sugar metabolism in cancer treatment."/>
Glucose, a common sugar in food, is one of the most important nutrients in the body. Cancer cells tend to consume it at an astounding pace. At first glance, that seems to make good sense because cancer cells have a lot of synthesis to do. After all, as tumors grow rapidly, each cell has to replicate its entire contents.
But here’s the catch. Cancer cells don’t use the glucose very efficiently. Instead of sucking all of the energy they can out of glucose, they release most of it as a waste material.
“To extract the maximum amount of energy from glucose, cells must transport its transformation products into mitochondria,” said Gary Patti, the Michael and Tana Powell Professor of Chemistry in Arts &amp; Sciences and of genetics and of medicine at the School of Medicine. Patti, a member of Siteman Cancer Center at Barnes-Jewish Hospital and the School of Medicine, is senior author of the new study.
“There are certain biochemical rules that metabolism is supposed to follow. It’s been interesting to think about why tumors might be allowed to break them,” Patti said. “However, the findings we report here demonstrate that cancer cells do follow conventional principles.”
<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Washington_University_in_St_Louis_Wash_U_leads_new_multi_omics_production_center_for_NIH_research_consortium_Patti_fa8e4a9e2a/Washington-University-in-St.-Louis-WashU-leads-new-multi-omics-production-center-for-NIH-research-consortium-Patti.jpg" alt="Washington University in St. Louis: Patti."/>
<h4>Overflowing</h4>
Mitochondria are tiny compartments inside cells, often referred to as the cell’s power plants or powerhouses. What goes in and out of them is tightly controlled.
As a bit of backstory, a famous biochemist named Otto Warburg first discovered the wasteful nature of tumors in the 1920s. To explain why more energy isn’t harvested from glucose, he postulated that mitochondria are damaged in cancer cells.
“We now know that this is not true. Mitochondria are functional and, in fact, active in most cancers,” Patti said. But that leaves a persistent and vexing question unanswered: Why do cancer cells metabolize so little of the glucose they consume in mitochondria?
“I think what has been confounding is that there has been this notion that cancer cells prefer not to oxidize glucose in their mitochondria,” Patti said. “Perhaps as a legacy of Warburg’s original thinking or maybe because it happens so extensively, the assumption has often been that cancer cells want to use glucose wastefully.”
<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Washington_University_in_St_Louis_Shutterstock_Sugar_metabolism_is_surprisingly_conventional_in_cancer_c350558047.jpg" alt="Washington University in St. Louis/Shutterstock"/>
“When we restrict the amount of glucose taken up by cancer cells, almost all of it makes its way into mitochondria,” Patti said. “But as glucose consumption is increased, the speed of moving glucose-derived molecules into mitochondria can’t keep up.”
In other words, cancer cells only waste glucose away because transport into mitochondria is too slow.
Imagine a bathtub faucet that is spitting out water faster than the drain can remove it. Eventually, the water overflows onto the floor.
“This is not a radically new metabolic paradigm. Most cells do prefer to oxidize glucose in mitochondria rather than excrete it as waste,” Patti said. “Our data suggest that cancer cells are not an exception. They appear to follow the same biochemical patterns as other cells.”
All sorts of explanations have been offered as to why cancer cells might want to be wasteful with their glucose. However, Patti and his team contend that these rationalizations may be unnecessary. In the end, cancer metabolism may not be as unusual as scientists thought.
Cancer cells really do want to metabolize glucose in their mitochondria, and they do so. Until they can’t.
<h4>Saturated</h4>
The Patti team’s discovery was made possible by a powerful technology called metabolomics.
“During the past decade, advances in the field of metabolomics and mass spectrometry have been extraordinary,” Patti noted. “We have now reached a point where measuring molecules in single cells is even possible.”
In this study, the researchers combined metabolomics with stable isotope tracers. This allowed them to tag different parts of glucose so that they could track it inside of cells, watching the speed at which things entered mitochondria or were excreted from cells. That is how the scientists discovered that the normal pathways for transporting fuel were getting outpaced, or saturated, in cancer cells.
The rate at which tumors consume glucose has been exploited by doctors in the clinic for decades as a way to diagnose cancer and identify its stage. It also has led some to believe that limiting glucose uptake with drugs or by eating a sugar-free diet might “starve” the cancer cells to death.
This study’s findings raise questions about such a strategy.
“We may need to rethink how best to target glucose metabolism in cancer,” Patti said. “If cancer cells take up more glucose than they need, and using it wastefully is not a driver of disease, then glucose metabolism may not be as attractive of a therapeutic target as we had hoped.”
<h6>Funding: Financial support was received for this work from NIH awards R35ES028365 and R24OD024624, as well as the Edward Mallinckrodt Jr. Foundation and the Pew Charitable Trusts.</h6>

Sugar metabolism is surprisingly conventional in cancer

A new study with zebrafish shows that a deadly form of skin cancer — melanoma — alters the metabolism of healthy tissues elsewhere in the body. The research from Washington University in St. Louis suggests that these other tissues could potentially be targeted to help treat cancer.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Washington_University_in_St_Louis_Cancer_has_ripple_effect_on_distant_tissues_Patti_bca1fbd7a0.jpg" alt="Washington University in St. Louis: Patti." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Washington_University_in_St_Louis_Cancer_has_ripple_effect_on_distant_tissues_Patti_bca1fbd7a0.jpg 228w," sizes="100vw" width="1400" height="959">“Tumors rely on a constant supply of nutrients to grow. Instead of competing with tumors for nutrients, other tissues can reprogram their metabolism to be complementary. In some instances, this may even allow healthy tissues to feed the tumor,” said <a target="_blank" rel="noopener noreferrer" href="https://chemistry.wustl.edu/people/gary-patti">Gary Patti</a>, the Michael and Tana Powell Professor of Chemistry in Arts &amp; Sciences at Washington University and a professor of chemistry and medicine at the School of Medicine.Patti is the corresponding author of the study published May 13 in <a target="_blank" rel="noopener noreferrer" href="https://www.cell.com/cell-metabolism/fulltext/S1550-4131(21)00180-7">Cell Metabolism</a>.Cancer consumes tremendous amounts of glucose, a key source of energy for cells in the body. Glucose, or blood sugar, is derived from food and transported around the body through the bloodstream after eating. Tumors actively soak up glucose as a fuel to support their rapid growth.This trait is so well known that physicians regularly use it as a diagnostic test for cancer, where patients are administered a specific form of glucose that can be monitored with a PET scan. What is less clear is how a tumor’s penchant for glucose affects other tissues.“Glucose levels are tightly regulated,” Patti said. “When glucose levels get too low, it’s dangerous. We wanted to know whether a tumor with a high avidity for glucose might influence glucose levels in the blood.”Even when healthy people go a long period of time without eating, blood glucose levels are kept relatively constant. That is because glucose can be made by the liver when it cannot be obtained directly from food.“As it turns out, the liver counters the impact of the tumor by synthesizing glucose,” Patti said. “It’s very similar to what occurs during a fast.”<blockquote><h5>What is metabolic crosstalk?</h5><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Washington_University_in_St_Louis_Cancer_has_ripple_effect_on_distant_tissues_afa2b13b9e.jpg" alt="Washington University in St. Louis: Cancer has ripple effect on distant tissues." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Washington_University_in_St_Louis_Cancer_has_ripple_effect_on_distant_tissues_afa2b13b9e.jpg 214w," sizes="100vw" width="1125" height="820"><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/articles?search=Gary+Patti">Gary Patti</a> is an expert in the field of <a target="_blank" rel="noopener noreferrer" href="https://source.washu.edu/2018/10/metabolomics-for-the-masses/">metabolomics</a>, the comprehensive study of small molecules within a biological system.“In metabolic crosstalk, two tissues within one biological system exchange molecules,” Patti explained.“One tissue takes up a metabolite and transforms it into a different molecule that is released. The released molecule is then taken up by another tissue,” Patti said. “Imagine that happening a bunch of times with metabolites flowing in bidirectional ways between various pairs of tissues.”</blockquote>Working with zebrafish, Patti and co-authors including other researchers at the School of Medicine developed a new approach to study melanoma’s impact on different tissues in the body that uses a technology called metabolomics.The scientists fed the zebrafish special versions of nutrients tagged with isotope labels. These labels allowed the scientists to track where nutrients go and into what molecules they get broken down. They found that a molecule being spit out by the tumor was being taken up by the liver to make glucose.By applying metabolomics to individual zebrafish, the scientists observed that melanoma tissues in the body consume about 15 times more glucose than the other tissues they measured. Despite this burden, the zebrafish were able to maintain circulating glucose levels, apparently by making glucose in the liver through a process that is ordinarily triggered when we go without eating.But it was clear that otherwise healthy tissues were affected in many ways by the presence of melanoma.The scientists examined tissues in the liver, intestine, fin, muscle, brain, blood, and eye of the zebrafish. They observed metabolic dysregulation across most of the tissues — indicating that melanoma broadly impacts whole-body metabolism.“There is clear metabolic crosstalk between melanoma and other tissues,” Patti said. “The metabolic relationship between melanoma and liver is partly characterized by a gene called BCAT1 in the cancer cells. BCAT1 goes from essentially being turned off in healthy skin cells to being highly expressed in zebrafish melanoma. By looking at melanoma from human patients, we were able to confirm that the same pattern holds in people.”Much of the previous research on cancer has focused on the metabolism of the tumor itself.“Our work shows that a lot of interesting metabolic changes are also occurring beyond the tumor,” Patti said. “We have demonstrated that, at least in some cases, these metabolic changes in non-malignant tissues occur to support the tumor. This is exciting because it means that we might be able to target the metabolism of healthy tissues as a potential treatment for cancer.”<blockquote>A special note: The authors of this paper dedicated their work to the late Stephen L. Johnson, who was an inspiring mentor to them. His collaborative generosity was essential to carrying out these studies. Read more about Johnson on the School of Medicine <a target="_blank" rel="noopener noreferrer" href="https://medicine.wustl.edu/news/obituary-stephen-l-johnson-professor-genetics-56">website</a>.</blockquote>Financial support was received for this work from National Institutes of Health awards R35ES028365, U01CA235482, and R24OD024624, as well as the Edward Mallinckrodt, Jr. Foundation and the Pew Charitable Trusts.

Cancer has ripple effect on distant tissues

Batteries have become so integral to everyday life – powering everything from mobile devices to electric vehicles and renewable energy storage systems – that people often don’t even think about them. But our increasing reliance on batteries has made considerations like their sustainability and ability to hold charge in a range of environments and the ability to reliably source materials needed to produce them urgent considerations.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Washington_University_in_St_Louis_Peng_Bai_Rajeev_Gopal_and_Ethan_Boutelle_Beyond_lithium_Sodium_based_batteries_may_power_the_future_Peng_Bai_s_research_group_combines_stable_536989e74c.jpg" alt="Washington University in St. Louis / Peng Bai, Rajeev Gopal and Ethan Boutelle: Peng Bai’s research group combines stable sodium metal plated in liquid electrolyte (left) with precisely engineered particles of sodium vanadium phosphate (right) to create safe and efficient sodium batteries." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Washington_University_in_St_Louis_Peng_Bai_Rajeev_Gopal_and_Ethan_Boutelle_Beyond_lithium_Sodium_based_batteries_may_power_the_future_Peng_Bai_s_research_group_combines_stable_536989e74c.jpg 234w," sizes="100vw" width="1200" height="800"><a target="_blank" rel="noopener noreferrer" href="https://engineering.washu.edu/faculty/Peng-Bai.html">Peng Bai</a>, associate professor of energy, environmental &amp; chemical engineering in the McKelvey School of Engineering at Washington University in St. Louis, received a two-year, $550,000 Partnerships for Innovation – Technology Translation award from the National Science Foundation to support his work on sodium-based batteries. The award will allow Bai to expand his prior NSF-funded research to scale up and commercialize his sodium battery technology.&nbsp;Bai’s sodium-based batteries deliberately move away from lithium and other rare elements used in traditional batteries. Sodium, a more abundant and easier to process material, promises lower production costs and alleviated supply chain vulnerabilities, fostering a more sustainable and economically efficient energy landscape. Sodium-based batteries may also offer enhanced fast-charging capabilities and improved operation in cold environments, expanding their potential application in large-scale energy storage and portable electronics, including electric vehicles.The project, “<a target="_blank" rel="noopener noreferrer" href="https://www.nsf.gov/awardsearch/showAward?AWD_ID=2431923">Development of high-performance long-life electrodes for sustainable sodium-based batteries</a>,” has three main goals: ensuring consistency in larger production batches, developing greener manufacturing processes using water instead of toxic solvents, and optimizing production processes at a commercial scale. These advancements would pave the way for sodium-based batteries to make their way into everyday technologies within five years, Bai says.

Beyond lithium: Sodium-based batteries may power the future

Article

Product

Events

Webinars

Application

Academy

Video

Poster

Scientists

Plastics

Environment

Food

Water

Health

Presentation

Scientific article

Interview

Toxicology

Popularization

Science and research

Software

Covid-19

Career

Laboratories

Various

Zaměření

Type of News

Focus

Washington University in St. Louis is a place where people matter and serious work is done.

Our mission is to discover and disseminate knowledge, and to protect the freedom of inquiry through research, teaching and learning.

We are a community where you can be an individual and achieve exceptional things. We are committed to learning and exploration, to discovery and impact.

Washington University in St. Louis

Pittcon 2026

36th MassSpec Forum Vienna 2026

US HUPO 2026

The science of next-gen ingredients: fermentation, formulation and function

Small Size, Big Impact – High-Performance Benchtop GC and GC/MS with the Agilent 8850 GC

Dynamic Blender